Navigation Links
Black Rectal Cancer Patients Less Likely to Get Chemo, Radiation
Date:5/13/2008

See oncologists as often as whites, researchers not sure why different choices of treatment follow

TUESDAY, May 13 (HealthDay News) -- Even though black and white rectal cancer patients have similar referral rates to oncologists, blacks are less likely to receive chemotherapy or radiation therapy, new research shows.

In their study, researchers from the University of Michigan Comprehensive Cancer Center looked at 2,582 white patients and 134 black patients, aged 66 and older.

The study found that 75 percent of whites and 73 percent of blacks saw an oncologist after being diagnosed with rectal cancer, but only 54 percent of blacks received chemotherapy, compared with 70 percent of whites. In addition, rates of referral to a radiation oncologist were similar, but only 74 percent of blacks received radiation therapy, compared with 83 percent of whites.

The findings were published in the May 13 online issue of the Journal of the National Cancer Institute.

"Although there wasn't a discrepancy between African-Americans and whites in the rates of consultation with an oncologist, we found a large discrepancy in the receipt of chemotherapy. This is very important. We knew that African-Americans were not receiving chemotherapy for rectal cancer at the same rates as white Americans, and it was contributing to their increased mortality. Now we have a better idea of where the problem lies: somewhere between the visit with the oncologist and the actual initiation of chemotherapy," study author Dr. Arden Morris, an assistant professor of surgery at the U-M Medical School and chief of general surgery at the VA Ann Arbor Healthcare System, said in a prepared statement.

Compared to whites, blacks have as much as a 20 percent worse long-term survival rate after rectal cancer surgery. It's known that the use of chemotherapy and radiation improves survival in all rectal cancer patients by as much as 20 percent. It's believed that the lack of chemotherapy and radiation treatment in blacks is largely responsible for their lower long-term survival rates.

"We now know that the initial visit with an oncologist is not the barrier to treatment. Our next step is to better understand what are the human factors that contribute to this discrepancy. We're interested in hearing what individual people have to say," Morris said.

She and her colleagues suspect social differences and priorities among different groups -- such as patient preferences or access to resources such as transportation or family care -- may contribute to these discrepancies.

"Choice is important. If there's a choice, this maybe isn't a disparity but a preference. But if it's not a choice, then we need to understand the barriers and find solutions," Morris said.

In her next study, she plans to interview patients who've been treated for colorectal cancer to learn how they reached the decision to have chemotherapy or whether they feel they even made that decision themselves.

More information

The U.S. National Cancer Institute has more about colorectal cancer.



-- Robert Preidt



SOURCE: University of Michigan news release, May 13, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Media Alert: 100 Black Men of Atlanta Host 3rd Annual Community Health Fair
2. Black women have urinary incontinence less than half as often as white women
3. Gene Variant Protects Black Heart Failure Patients
4. Muscle Mass May Not Explain High Creatinine in Black Kidney Patients
5. Blackstone Sells Gerresheimer Stake
6. Breast Cancer Unchanged in Black Women, Despite Drop in HRT Use
7. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
8. Joint Center to Focus on Issues of Health Equity During Congressional Black Caucus Spring Health Braintrust
9. High-Risk Blacks Less Likely to Get Colonoscopies
10. Black Infants Are More Likely to Be Born Preterm and to Die at Birth
11. Glaucoma May Boost Cardiovascular Death Risk in Blacks
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Black Rectal Cancer Patients Less Likely to Get Chemo, Radiation
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... DrugDev ... study is whether they can trust the sponsor to pay them correctly and on ... sponsors and CROs establish payment strategies that encourage sites to work on their studies. ...
(Date:6/27/2017)... ... 2017 , ... The Congressional Budget Office (CBO) projects that the Better Care ... Protection and Affordable Care Act (ACA), would result in 22 million Americans losing their ... , More than 20 million Americans have gained health insurance under the ACA, and ...
(Date:6/27/2017)... ... , ... A January 18th article on medGadget reports that the ... the year 2024 according to a new report. The article also notes that the ... Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that it ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... HORSHAM, Pa. , June 19, 2017  Researchers ... announced today that they will host a live, complimentary ... Perspectives from the benchtop to the real world" on ... PM EDT. This webinar will feature ... a rare look into the manipulation techniques abusers use ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: